Скачать с ютуб Symposium | Panel discussion | Strategies for the management of treatment-related toxicities in MM в хорошем качестве

Symposium | Panel discussion | Strategies for the management of treatment-related toxicities in MM

This independent educational activity was supported by GSK. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity. At the European School of Haematology (ESH) 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium titled: How to sequence B-cell maturation antigen (BCMA)-directed therapies in early relapsed/refractory multiple myeloma (RRMM). Mohamad Mohty chaired a second panel discussion, focusing on the strategies for the management of treatment-related toxicities in MM, joined by expert speakers Martin Kaiser and Rakesh Popat. In this panel discussion, the speakers addressed key considerations when managing treatment-related toxicities, particularly with advanced and targeted therapies in MM. The conversation focused on the use of belantamab mafodotin in both relapsed and first-line settings, emphasizing the importance of optimizing quality of life and managing side effects, without sacrificing outcomes. The speakers explored belantamab mafodotin-based combinations, highlighting dosing strategies to minimize ocular toxicities.